<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02922712</url>
  </required_header>
  <id_info>
    <org_study_id>DRL_RUS/MMD/2011/CT/NISE</org_study_id>
    <nct_id>NCT02922712</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Nise 100 mg in the Management of Osteoarthrosis (Gonarthrosis)</brief_title>
  <acronym>NISE-2013</acronym>
  <official_title>Evaluation of Clinical Efficacy and Safety of the Drug Nise (Nimesulide) in Complex Treatment of Patients With Osteoarthritis of the Knee and Hip Joints</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study is conducted to evaluate safety and efficacy in patients with osteoarthritis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoarthritis is the most common disorders of the joints, which gives a page more than 10%&#xD;
      of the world population aged over 45 years (Woolf A. D., Pfleger B., Bergman S., 2009). The&#xD;
      main clinical manifestations of the disease are pain in the joints and a violation of their&#xD;
      functions. Therefore, one of the first tasks in the therapeutic program, these patients will&#xD;
      decrease and possible pain relief. Nesteroi dnye anti-inflammatory drugs (NSAIDs) are the&#xD;
      main group of medicines drugs used in medical practice in lech th Research Institute of pain&#xD;
      in patients with lesions of the musculoskeletal system. The basis of the therapeutic effect&#xD;
      of the second of these drugs is the suppression of the activity of Fe p IU NTA cyclooxygenase&#xD;
      (COX). Prichё m, the suppression of the activity of COX-2 isoenzyme involved in the synthesis&#xD;
      of prostaglandins, induce the development of pain and PLAYBACK tion and provides&#xD;
      anti-inflammatory effects of NSAIDs. B Blocking out of the enzyme COX-1, which controls the&#xD;
      synthesis of prostaglandins, have cited a protective properties, leading to side effects of&#xD;
      NSAIDs These so called nye formed the basis for the creation of new NSAIDs that can&#xD;
      selectively inhibit COX-2 and m and mally affect COX. - 1.&#xD;
&#xD;
      Nimesulide is a selective inhibitor of cyclooxygenase -2 vnym with Sat and anced analgesic&#xD;
      and anti-inflammatory effect, but also has antibradikinin, antihistamine and antioxidant&#xD;
      activity of Stu(Nasonov EL, 1999, 2001).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Pain Intensity on VAS</measure>
    <time_frame>From baseline to 3 week</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>NISE 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nise 100mg given BD for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NISE</intervention_name>
    <description>Nise 200mg Max per day in 2 divided doses</description>
    <arm_group_label>NISE 100mg</arm_group_label>
    <other_name>Nimesulide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients 40 years old and older with verified diagnosis of OA of the knee joints&#xD;
             according to the criteria of American College of Rheumatology (АСR);&#xD;
&#xD;
          -  radiologic abnormalities complying with I-III grades of Kellgren;&#xD;
&#xD;
          -  pain syndrome not less than 40 points according to 100-point visual analogue scale&#xD;
             (VAS).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of the patient within the last 5 years malignancy of any organ or system&#xD;
             regardless of whether the treatment and is carried on this occasion elk.&#xD;
&#xD;
          -  The presence of acute ulcer disease of the gastrointestinal tract that is, over&#xD;
             several recent years.&#xD;
&#xD;
          -  Any data on the bleeding from the upper gastrointestinal tract.&#xD;
&#xD;
          -  Severe disease: uncontrolled hypertension, expression n naya cardiovascular failure, a&#xD;
             pathology of the hematopoietic system, and mellitus type I, and others.&#xD;
&#xD;
          -  The presence of other rheumatic diseases with the exception of teoartroza.&#xD;
&#xD;
          -  Liver disease (cirrhosis, chronic hepatitis).&#xD;
&#xD;
          -  Abnormal liver function (ALT, AST, bilirubin more than 1.5 times the upper limit of&#xD;
             normal).&#xD;
&#xD;
          -  Impaired renal function (blood creatinine more than 1.5 times higher than it's ver&#xD;
             limit of normal).&#xD;
&#xD;
          -  Anemia (g emoglobin more than 10 g / l less than the lower limit of normal).&#xD;
&#xD;
          -  Treatment with corticosteroids (systemic reception), warfarin and other coumarin&#xD;
             governmental produ d.&#xD;
&#xD;
          -  Hypersensitivity to the analgesic and antipyretic Wed d stvam, NSAIDs, sulfonamides.&#xD;
&#xD;
          -  Pregnancy and lactation.&#xD;
&#xD;
          -  Alcohol and drug abuse history.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew E. Pihlak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budgetary Institution of Higher Professional Education &quot;A.I. Evdokimov Moscow State Medical Dental University&quot; of the Ministry of Health of Russia</affiliation>
  </overall_official>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>October 3, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>October 3, 2016</last_update_submitted>
  <last_update_submitted_qc>October 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimesulide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

